REG - RUA Life Sciences - Result of AGM

Rua Life SciencesAnnouncement

28/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240828:nRSb8926Ba&default-theme=true

RNS Number : 8926B  RUA Life Sciences PLC  28 August 2024

28 August 2024

 

RUA Life Sciences plc

("RUA" the "Company" or the "Group")

Result of AGM

 

RUA Life Sciences plc (AIM:RUA.L), the holding company of a group of medical
device businesses focussed on the exploitation of the world's leading
long-term implantable biostable polymer (Elast-Eon ™), announces that all
resolutions put forward to its Annual General Meeting held yesterday were duly
passed and the votes cast were as follows:

 

 Res No.  Votes For  %       Votes Against  %      Votes Withheld
 01       6,051,300  99.37%  38,570         0.63%  0
 02       6,050,279  99.36%  38,783         0.64%  808
 03       6,051,300  99.37%  38,570         0.63%  0
 04       6,045,927  99.28%  43,943         0.72%  0
 05       6,045,698  99.27%  44,172         0.73%  0
 06       5,941,757  97.57%  148,113        2.43%  0
 07       5,941,757  97.57%  148,113        2.43%  0

 

The full text of each of the resolutions is set out in the notice of Annual
General Meeting, copies of which are available on the Company's website
(www.rualifesciences.com (http://www.rualifesciences.com/) ).

 

For further information contact:

 RUA Life Sciences                                 Tel: +44 (0)1294 317073
 Bill Brown, CEO
 Lachlan Smith, CFO

 Cavendish Capital Markets Limited
 (Nominated Adviser and Broker)                    Tel: +44 (0)20 7220 0500
 Giles Balleny/Dan Hodkinson (Corporate Finance)
 Charlie Combe (Broking)
 Michael Johnson (Sales)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGPRMPTMTTTBAI